Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892548 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
A Phase 1 study of Advanced Lung Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 594
- Enrollment target
- 20
- Study locations
NCT06892548 is a Phase 1 study of Advanced Lung Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 594 participants, above the 277-participant average among 3 other Advanced Lung Cancer trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06892548, a Phase 1 study of Advanced Lung Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 594 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- BIOLOGICAL BNT324
- BIOLOGICAL BNT327
Study Locations (20)
California
- Precision NextGen Oncology and Research Center - Beverly Hills
- Cedars Sinai Medical Center - Los Angeles
- UCLA - David Geffen School of Medicine - Santa Monica
Texas
- Texas Oncology - DFW - Dallas
- MD Anderson Cancer Center - Houston
- Texas Oncology - Northeast - Tyler
Victoria
- Bendigo Hospital - Bendigo
- Barwon Health - Geelong
- Sunshine Hospital - Saint Albans
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
- Icahn School of Medicine at Mount Sinai PRIME - New York
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Iowa
- University of Iowa Hospitals & Clinics PARENT - Iowa City
Minnesota
- Mayo Clinic-Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06892548
The ClinicalTrials.gov registry entry for NCT06892548 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 277-participant average among 3 other Advanced Lung Cancer trials with a reported enrollment target (114% higher). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which BNT324 is the first listed.
NCT06892548 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Victoria.
Frequently Asked Questions
What is clinical trial NCT06892548 about?
NCT06892548 is a clinical study titled "A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer". This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer ...
What is the current status of trial NCT06892548?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 594 participants. The study started on 2025-05-02. Estimated completion is 2031-06.
What conditions does trial NCT06892548 study?
This clinical trial studies the following conditions: Advanced Lung Cancer.
What interventions are being tested in trial NCT06892548?
The interventions under investigation include: BNT324 (BIOLOGICAL), BNT327 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06892548?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892548 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.